UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-K WASHINGTON, D.C. 20549 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 001-39825 Intelligent Bio Solutions Inc. (Exact name of Registrant as specified in its Charter) Delaware 82-1512711 (State or oth ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 001-39825 Intelligent Bio Solutions Inc. (Exact name of Registrant as specified in its Charter) Delaware 82-1512711 (Sta ...

Acquisition and Expansion - The company completed the acquisition of Intelligent Fingerprinting Limited (IFP) on October 4, 2022, expanding its portfolio of rapid, non-invasive diagnostic testing technologies[168]. - The IFP acquisition involved issuing 2,963,091 shares of common stock and 2,363,003 shares of Series C Convertible Preferred Stock as consideration[169]. - IFP expanded its customer base by entering sales contracts with several UK companies, including Glass Systems and Eastern Airways[180]. - The company aims to increase market share in the UK and West Europe while commencing distribution in the Asia region and pursuing FDA regulatory approval for the US market[175]. Financial Performance - Revenue from sales of goods increased from $0 to $356,679 for the quarter ended December 31, 2022, compared to the same period in 2021, due to the acquisition of Intelligent Fingerprinting Limited (IFP) during the current quarter[199]. - Gross profit for the quarter ended December 31, 2022, was $244,044, with total operating expenses of $2,644,636, resulting in a loss from operations of $2,130,967[198]. - The net loss for the quarter ended December 31, 2022, was $427,071, compared to a net loss of $3,463,823 for the same period in 2021[198]. - The total comprehensive loss for the six months ended December 31, 2022, was $1,415,111, compared to a comprehensive loss of $4,961,790 for the same period in 2021[198]. - Cash and cash equivalents as of December 31, 2022, were $2,911,682, with working capital of $1,563,530[226]. - The company expects its cash and cash equivalents will be insufficient to fund its current operating plan for at least the next twelve months[227]. Research and Development - The company is developing a Saliva Glucose Biosensor (SGB) to replace invasive blood glucose monitoring for diabetic patients, with ongoing clinical studies involving 40 adult subjects[174]. - The Saliva Glucose Test (SGT) is expected to substitute invasive blood glucose monitoring for diabetic patients, utilizing a non-invasive method to measure glucose levels in saliva[188]. - The Biosensor Platform Technology allows for the detection of multiple biological analytes, with the potential to develop tests for cancer biomarkers and hormones[197]. - The SGB (Saliva Glucose Biosensor) can detect glucose in saliva at concentrations between 8 and 200 µM, exhibiting sensitivity 100 times lower than blood glucose levels[190]. - The company has completed the development of an intermediate device that communicates with smart devices, enhancing the functionality of the SGB[194]. - The company is developing an R&D and manufacturing facility at the University of Newcastle, Australia, with construction expected to start in Q2 2023[180]. Stock and Shareholder Information - A reverse stock split at a ratio of 1-for-20 became effective on February 9, 2023, reducing the number of outstanding shares from approximately 18.3 million to about 916,265[178]. - The company has reserved up to 1,649,273 shares of Series C Preferred Stock for potential future issuance related to the IFP acquisition and employee stock options[170]. - The weighted average shares outstanding for the quarter ended December 31, 2022, was 908,283, compared to 744,126 for the same period in 2021[198]. Government Support and Expenses - The company reported government support income of $269,625 for the quarter ended December 31, 2022, compared to $177,791 for the same period in 2021[198]. - General and administrative expenses increased by $1,242,045 to $2,245,289 for the quarter ended December 31, 2022, compared to $1,003,244 in the same period in 2021, largely due to the acquisition of IFP[207]. - Development and regulatory expenses decreased by $2,639,991 to $1,191 for the quarter ended December 31, 2022, compared to $2,641,182 in the same period in 2021[210]. - Government support income in the IFPG and SGBP segments increased by $91,834 to $269,625 for the quarter ended December 31, 2022, compared to $177,791 in the same period in 2021[203]. Other Financial Metrics - The outstanding fair value of convertible notes as of December 31, 2022, was $523,703, with an interest rate of 17% per annum[230]. - Unrealized foreign currency translation gain increased by $354,242 to $361,597 for the quarter ended December 31, 2022, compared to $7,355 in the same period in 2021[221]. - Net loss attributable to INBS decreased by $3,039,398 to $420,600 for the quarter ended December 31, 2022, compared to $3,459,998 in the same period in 2021[223].

Intelligent Bio Solutions Inc. (NASDAQ:INBS) Q1 2023 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Harry Simeonidis - Chairman and CEO Spiro Sakiris - Chief Financial Officer Philip Hand - Executive Chairman, Intelligent Fingerprinting Limited Conference Call Participants John Vandermosten - Zacks Operator Greetings. And welcome to the Intelligent Bio Solutions Inc. First Quarter 2023 Earnings Conference Call. Currently, all participants are in listen-only mode. A question-and-an ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 001-39825 Intelligent Bio Solutions Inc. (Exact name of Registrant as specified in its Charter) Delaware 82-1512711 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 001-39825 GBS Inc. (Exact name of Registrant as specified in its Charter) Delaware 82-1512711 (State or other jurisdiction of inc ...

GBS, Inc. (GBS) Q4 2022 Earnings Conference Call August 31, 2022 4:30 PM ET Company Participants Steven Boyages - Chairman and Interim CEO Spiro Sakiris - CFO Conference Call Participants John Vandermosten - Zacks SCR Operator Greetings, and thank you for joining us for GBS, Inc's Fourth Quarter and Fiscal Yearend 2022 Financial and Business Update Conference Call. Currently all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, today's ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number 001-39825 GBS Inc. (Exact name of Registrant as specified in its Charter) Delaware 82-1512711 (State or other jurisdicti ...

GBS Inc. (GBS) Q3 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Dr. Steven Boyages - Chairman and Interim CEO Spiro Sakiris - Chief Financial Officer Conference Call Participants John Vandermosten - Zacks Operator Greetings. And welcome to the GBS Inc. Third Quarter 2022 Earnings Conference Call. Currently, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being ...

GBS Inc. (GBS) Q2 2022 Results Conference Call February 10, 2021 4:30 PM ET Company Participants Tim McCarthy - Investor Relations Steven Boyages - Chairman and Chief Executive Officer Spiro Sakiris - Chief Financial Officer Conference Call Participants John Vandermosten - Zacks Small Capital Research Ted Yu - Zacks Small Capital Research Operator Greetings, and welcome to the GBS Inc. Second Quarter 2022 Earnings Conference Call. Currently, all participants are on a listen-only mode. A question-and-answer ...